Tear proteomics is emerging as a powerful, non-invasive approach for early disease screening and personalized medicine. This whitepaper examines the molecular composition of tear fluid and its growing role in identifying biomarkers for ocular, systemic, neurodegenerative, metabolic, and oncologic conditions.
Drawing on advances in mass spectrometry and proteomic analytics, it outlines how tear-based biomarkers can support early detection and disease staging for dry eye disease, diabetes, glaucoma, age-related macular degeneration, Alzheimer’s disease, Parkinson’s disease, and select cancers.
The paper highlights the clinical advantages of tear analysis—ease of collection, high protein concentration, and proximity to disease sites—while exploring how proteomics, when combined with emerging AI techniques, may redefine future diagnostic workflows. Tear-based diagnostics represent a scalable, patient-friendly alternative to traditional blood or tissue sampling.